2024
ICER Report Highlights $815 Million in Unjustified Drug Price Increases in 2023
ICER report, unsupported drug price hikes, 2023, pharmaceutical costs, healthcare spending
Keros Therapeutics Faces Major Setback as PAH Trial Dosing Suspended Over Safety Concerns
Keros Therapeutics, PAH trial, dosing suspension, safety concerns, pulmonary arterial hypertension, cibotercept (KER-012), Phase II TROPOS trial
Corcept’s ALS Drug Trial Misses Primary Endpoint, Yet Shows Promising Survival Benefit
Corcept Therapeutics, Dazucorilant, ALS (Amyotrophic Lateral Sclerosis), Phase 2 trial, Survival benefit, Fast Track Designation, Cortisol modulator
Bavarian Nordic Closes San Diego R&D Site, Lays Off 48 Employees
Bavarian Nordic, San Diego, R&D site closure, layoffs, pharmaceutical industry
Ocaliva (Obeticholic Acid) Linked to Increased Risk of Liver Failure in PBC Patients Without Cirrhosis
Ocaliva, obeticholic acid, primary biliary cholangitis (PBC), liver failure, liver injury, cirrhosis, FDA warning.
Lonza Announces Strategic Shift to Focus on CDMO Business, Exits Capsules & Health Ingredients
Lonza, CDMO, Capsules & Health Ingredients, Restructure, One Lonza Strategy
Pleno Secures $25M Funding for Commercial Launch, Appoints New CEO from Illumina
Pleno, multiomics, funding, commercial launch, new CEO, Illumina
SIGA’s TPOXX Fails to Demonstrate Efficacy in Treating Mild to Moderate Mpox Cases: STOMP Study Results
SIGA Technologies, TPOXX, Tecovirimat, Mpox, STOMP Study, Antiviral Treatment, Efficacy, Safety Profile
Eli Lilly and Ro Partner to Expand Access to Affordable Zepbound Single-Dose Vials for Obesity Treatment
Eli Lilly, Ro, Zepbound, Single-dose vials, Obesity treatment, Telehealth, Affordable medication, Self-pay pharmacy
Candel Therapeutics Sees Dramatic Stock Surge Following Successful Phase III Prostate Cancer Trial
Candel Therapeutics, CAN-2409, Phase III trial, prostate cancer, viral immunotherapy, stock surge, FDA approval